Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The molecule designated "novel protein, readthrough PFDN5-C12orf10" (ENSG00000288663) is classified as a long non-coding RNA resulting from transcriptional readthrough between the adjacent protein-coding genes PFDN5 and C12orf10 on human chromosome 12[5][1]. It does not code for a protein and lacks functional characterization in the biomedical literature. The annotation reflects a genomic event—readthrough transcription—rather than a discrete molecular entity or validated therapeutic target. The biological significance, if any, has not been experimentally established, and it is not regarded as a target for drug development or as a disease biomarker. Any related functional or therapeutic interest should focus on the canonical genes: *Prefoldin subunit 5* (PFDN5) and *MYG1 Exonuclease* (C12orf10)[5][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel protein, readthrough PFDN5-C12orf10.